Clovis Oncology Inc (CLVS) : Iguana Healthcare Management scooped up 235,000 additional shares in Clovis Oncology Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 325,000 shares of Clovis Oncology Inc which is valued at $11,537,500.Clovis Oncology Inc makes up approximately 5.30% of Iguana Healthcare Management’s portfolio.
Other Hedge Funds, Including , Schonfeld Strategic Advisors boosted its stake in CLVS in the latest quarter, The investment management firm added 121,882 additional shares and now holds a total of 146,322 shares of Clovis Oncology Inc which is valued at $5,194,431. Clovis Oncology Inc makes up approx 0.89% of Schonfeld Strategic Advisors’s portfolio.Blackrock Investment Management boosted its stake in CLVS in the latest quarter, The investment management firm added 1,831 additional shares and now holds a total of 119,281 shares of Clovis Oncology Inc which is valued at $3,265,914.Swiss National Bank reduced its stake in CLVS by selling 2,000 shares or 3.63% in the most recent quarter. The Hedge Fund company now holds 53,050 shares of CLVS which is valued at $1,452,509.Cypress Capital Management (wy) boosted its stake in CLVS in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 1,000 shares of Clovis Oncology Inc which is valued at $27,380. Clovis Oncology Inc makes up approx 0.04% of Cypress Capital Management (wy)’s portfolio. Quantbot Technologies Lp added CLVS to its portfolio by purchasing 2,867 company shares during the most recent quarter which is valued at $81,796. Clovis Oncology Inc makes up approx 0.01% of Quantbot Technologies Lp’s portfolio.
Clovis Oncology Inc closed down -0.57 points or -1.57% at $35.73 with 11,17,633 shares getting traded on Monday. Post opening the session at $36.36, the shares hit an intraday low of $35.23 and an intraday high of $36.73 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Clovis Oncology Inc reported $-1.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-1.95.During the same quarter in the previous year, the company posted $-2.62 EPS.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Chardan Capital Markets Initiated Clovis Oncology Inc on Oct 25, 2016 to “Sell”, Price Target of the shares are set at $15.Clovis Oncology Inc was Upgraded by Credit Suisse to ” Outperform” on Sep 21, 2016. Company shares were Reiterated by Stifel on Sep 21, 2016 to “Buy”, Firm has raised the Price Target to $ 45 from a previous price target of $30 .
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.